SEP-363856, a novel non-D2-receptor-binding medication, was found to be effective in a recent psychopharmacological research for the treatment of schizophrenia. The chemical is a full agonist for the trace amine-associated receptor 1 (TAAR1) as well as a partial agonist for the 5-hydroxytryptamin 1A (5-HT 1A) receptor. The TAAR1 ligand neuron, D-neuron, was discovered in the striatum and nucleus accumbens (Acc), a neuroleptic active location, in the human brain, but not in the monkey brain's analogous area. A total of 154 post-mortem brains were used to research human D-neuron functions, and a modified immunohistochemistry approach using high-quality antibodies against monoamine-related chemicals was used. In post-mortem brains with schizophrenia, the number of D-neuron in the caudate nucleus, putamen, and Acc was reduced. In Acc., the drop was statistically significant (p0.05). I suggested the "D-cell hypothesis of schizophrenia," which states that NSC dysfunction-based D-neuron decrease represents the cellular and molecular foundation of mesolimbic dopamine (DA) hyperactivity, progressive pathogenesis, and the therapeutic potential of TAAR1.
Author(S) Details
Keiko Ikemoto
Department of Psychiatry, Iwaki City Medical Center, Iwaki, Japan.
View Book:- https://stm.bookpi.org/RDMMR-V4/article/view/4185
No comments:
Post a Comment